Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Meiji/Solasia Plan Japan NDA for PTCL Med in First Half of 2021
June 16, 2020
- Taiho Files Aloxi for Pediatric Use
June 16, 2020
- Poteligeo Now Available in Germany: Kyowa Kirin
June 16, 2020
- Mitsubishi Tanabe Launches PIII Dersimelagon Study for Rare Protoporphyria, Targeting US Filing in FY2021
June 16, 2020
- Kaken’s Axillary Hyperhidrosis Treatment Hits Primary Goal in Japan PIII Study
June 16, 2020
- 26 Japan Drug Makers Generate 56.4% of Sales Overseas in FY2019, Shire Buy Gives Boost: Tally
June 15, 2020
- Otsuka’s ADHD Med Hits Primary Goal in US PIII Trials
June 15, 2020
- Takeda, Mitsubishi-UBS Asset JV to Collaborate in Shonan iPark Operations
June 15, 2020
- PeptiDream, US Merck Link Up to Develop COVID-19 Treatment
June 15, 2020
- Daiichi Sankyo to Kickstart COVID-19 Vaccine Development
June 15, 2020
- AbbVie Files Rinvoq for Psoriatic Arthritis in Japan
June 15, 2020
- Takeda to Divest 18 Non-Core Meds in Asia-Pacific to Celltrion for US$278 Million
June 12, 2020
- Ono/Seikagaku’s Novel Osteoarthritis Drug Delivers in Japan PIII for Knee Pain
June 12, 2020
- 100 mg Version of Vimpat IV Infusion Now Available in Japan: UCB
June 12, 2020
- Shonan iPark to Launch VC Consortium
June 12, 2020
- Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
June 11, 2020
- Sanofi Rolls Out Soliqua Injection SoloStar for Type 2 Diabetes in Japan
June 10, 2020
- Xofluza Shows Favorable Results in Patients at High Risk of Flu Complications in Global PIII: Shionogi
June 10, 2020
- Japan Ethical Drug Sales Up 2.6% in April: Crecon
June 10, 2020
- Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII
June 10, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…